parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.07 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in retinal amacrine cells	0.75
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	5 Parkinson's papers of 92	0.76
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 4053

receipt 4062: NRXN2 in dopamine neurons, braak

power: full sample -0.37 (p 0.127, n 18), 95% CI -0.72 to +0.11. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.37 (p 0.127, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.46 (p 0.052, n 18). could be the mix.
skeptic: leave-one-out range -0.51 to -0.29, sign flips 0; without severely affected donors -0.37 (p 0.127, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for NRXN2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 4061: NRXN2 in oligodendrocytes, braak

power: full sample -0.54 (p 0.021, n 18), 95% CI -0.80 to -0.10. the interval excludes zero: something may be there, smaller than a half can see.
confounder: adjusted for sex: -0.58 (p 0.012, n 18). holds up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.61 (p 0.0069, n 18). not the mix.
skeptic: leave-one-out range -0.61 to -0.48, sign flips 0; without severely affected donors -0.54 (p 0.021, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for NRXN2 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts